Cargando…
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
ATTR amyloidosis is a systemic, debilitating and fatal disease caused by transthyretin (TTR) amyloid accumulation. RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis. The vast majority of TTR, the soluble precursor of TT...
Autores principales: | Butler, James S., Chan, Amy, Costelha, Susete, Fishman, Shannon, Willoughby, Jennifer L. S., Borland, Todd D., Milstein, Stuart, Foster, Donald J., Gonçalves, Paula, Chen, Qingmin, Qin, June, Bettencourt, Brian R., Sah, Dinah W., Alvarez, Rene, Rajeev, Kallanthottathil G., Manoharan, Muthiah, Fitzgerald, Kevin, Meyers, Rachel E., Nochur, Saraswathy V., Saraiva, Maria J., Zimmermann, Tracy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898164/ https://www.ncbi.nlm.nih.gov/pubmed/27033334 http://dx.doi.org/10.3109/13506129.2016.1160882 |
Ejemplares similares
-
The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis
por: Moreira, João, et al.
Publicado: (2021) -
RNAi therapeutics: a potential new class of pharmaceutical drugs
por: Bumcrot, David, et al.
Publicado: (2006) -
Delivery of an anti‐transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons
por: Gomes, João R., et al.
Publicado: (2018) -
Modulation of the Mechanisms Driving Transthyretin Amyloidosis
por: Bezerra, Filipa, et al.
Publicado: (2020) -
Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis
por: Ferreira, Nelson, et al.
Publicado: (2019)